Cellectis Bioresearch Launches VizuCELL Cell Lines for Live Cell Imaging

Regulatory News:

Cellectis bioresearch, a subsidiary of Cellectis Group (Paris:ALCLS) (Alternext: ALCLS), the genome engineering specialist, announces the launch of VizuCELL cell lines, a tool for live cell imaging.

As live cell imaging has become a requisite analytical tool in most cell biology laboratories, Cellectis bioresearch has developed VizuCELL cell lines for biomedical research and cell biology.
VizuCELL cell lines offer an exceptional tool to study temporal and spatial dynamic processes in living cells in order to get critical insights into morphological changes and physiological events in real time.
VizuCELL are generated by utilizing our proprietary TALEN™ technology to tag endogenous genes with a fluorescent signal controlled by the endogenous promoter.
The VizuCELL product line comprises the most popular cell lines in imaging (HeLa and U-2 OS), which are large cells growing in monolayers, therefore enabling unambiguously visualization of cell organelles and the cytoskeleton.
VizuCELL is suitable for non-invasive long-term monitoring. Due to stable endogenous protein expression the obtained information mirrors models closer to real life. VizuCELL simplifies the experimental with ready-to go imaging for a faster and cost effective workflow.

For further information please visit our website www.cellectis-bioresearch.com
or contact@cellectis-bioresearch.com

About Cellectis bioresearch
Established in 2008 as a subsidiary of Cellectis, Cellectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning Custom TALEN™ Services. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.

About Cellectis
Founded in France in 1999, the Cellectis Group is based on a highly specific DNA engineering technology. Its application sectors are human health, agriculture and bio-energies. Co-created by André Choulika, its Chief Executive Officer, Cellectis is today one of the world leading companies in the field of genome engineering. Cellectis is also focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine. Cellectis leverages a deep experience in stem cell handling, scale-up and differentiation into mature and functional human cells. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States. Cellectis achieved in 2011 €16M revenues and has signed more than 80 industrial agreements with pharmaceutical laboratories, agrochemical and biotechnology companies since its inception. AFM, Dupont, BASF, Bayer, Limagrain, Novo Nordisk… are some of the Group’s clients and partners. Since 2007, Cellectis has been listed on NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For more information, visit our website: www.cellectis.com

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.